TenQ

The Nautilus Biotechnology story

Nautilus Biotechnology is developing instruments and assays to measure proteins, with commercialization depending on whether its shift toward specific protein variants can bring Voyager to market while broadscale development continues.

Nautilus Biotechnology stock reportTenQ Score 10/36 · every chart and check from its filings
  • $2.06share price, last close
  • $262Mmarket value
  • 10/36TenQ Score checks passed

The story in brief

  • First revenue arrives. Nautilus recognized $0.2 million of revenue in the quarter to June 2026, primarily from a Michael J. Fox Foundation grant, alongside its first Early Access Program service revenue.
  • A narrower launch path. Nautilus is reallocating resources toward proteoform assays, which measure functional protein variants, after broadscale testing failed to support general availability in 2027.
  • Commercialization remains costly. Operating expenses declined 7% to $15.9 million in the quarter to June 2026, but Nautilus still reported a net loss of $14.5 million.

What drives the business

  • Nautilus is building Voyager around Iterative Mapping, a method designed to count individual intact proteins and measure both protein abundance and functional variants on the same platform.
  • Its planned business model starts with analysis services and moves toward instruments, consumables, software and support, with recurring revenue intended to accompany instrument placements.
  • Research collaborations include Genentech, the Michael J. Fox Foundation and The Buck Institute for Research on Aging, alongside an agreement with the Allen Institute.
  • The Iterative Mapping Early Access Program launched in January 2026 with the Tau Proteoforms Assay, and the Michael J. Fox Foundation grant supports development of an alpha-synuclein proteoform assay.
  • Following customer interest in proteoforms, Nautilus selected AKT1 as its first oncology application and redirected resources toward these assays rather than adding spending, while delaying the Broadscale Assay to improve performance.

What the price assumes

At $1.96 per share and a market value of $249 million, the reverse DCF cannot measure an implied growth assumption because free cash flow and operating earnings are both negative, leaving the price dependent on future profits.

The operating record remains at the first revenue stage, with free cash flow of -$52 million over the last twelve months.

The free cash flow yield of -20.8% fails TenQ's above 3% check, and the absence of positive earnings or free cash flow prevents a comparison between price assumptions and an established profit growth record.

What could change the story

  • Development delays and insufficient functionality or market acceptance could prevent Nautilus from generating material revenue, and the company expects significant losses as it develops the business.
  • Dependence on single source suppliers for some Voyager components and materials adds another potential constraint on commercialization.
  • At June 2026, cash and short-term investments were $84 million, while the broader balance including long-term investments was $129.2 million, with total debt of $0.
  • TenQ's self-funding check indicates 1.62 years of cash at the measured burn rate using the narrower cash balance, so that measure does not capture the full investment portfolio.
  • The September 2026 at the market offering agreement with TD Securities provides a financing route, but issuing additional shares could dilute existing holders.

What to watch next

  • The next releases can show whether AKT1 enters Early Access in late 2026 and whether Voyager remains scheduled for pre-orders in early 2027, followed by instrument shipments and general availability of Tau and AKT1 consumable kits in mid 2027.
  • Additional service revenue and customer participation would help distinguish commercial demand from the grant revenue that primarily drove the quarter to June 2026.
  • Operating expenses, free cash flow and cash balances will show whether the proteoform shift stays within management's stated plan to reallocate resources without incremental spending.
  • A revised Broadscale Assay timeline and evidence of improved performance remain important unresolved milestones.

Sources

Back to the NAUT report